Home › Therapeutic areas › GI/Hepatology › Eosinophilic Esophagitis
Eosinophilic Esophagitis (4 companies)
Companies with an active program in Eosinophilic Esophagitis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | $619M | 8 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $69.0M | 9 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 1 | Approved | $1.39B | 9 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | — | 9 |
No companies match.